Zuckerman Investment Group LLC Has $26.16 Million Position in Kenvue Inc. $KVUE

Key Points

• Zuckerman Investment Group LLC reduced its stake in Kenvue Inc. by 2.8%, now holding over 1 million shares, which represents 2.8% of its portfolio.
• Kenvue has recently reported a quarterly dividend increase to $0.2075, yielding 3.9%, with a dividend payout ratio of 112.16%.
• Despite beating earnings expectations with $0.29 EPS, Kenvue's revenue was down 4.0% year-over-year, leading analysts to adjust their price targets for the stock.

Zuckerman Investment Group LLC lowered its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 2.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,091,041 shares of the company's stock after selling 31,020 shares during the period. Kenvue accounts for 2.8% of Zuckerman Investment Group LLC's portfolio, making the stock its 5th largest position. Zuckerman Investment Group LLC owned 0.06% of Kenvue worth $26,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. Epoch Investment Partners Inc. increased its position in shares of Kenvue by 53.0% in the 1st quarter. Epoch Investment Partners Inc. now owns 4,794,572 shares of the company's stock valued at $114,974,000 after buying an additional 1,660,329 shares in the last quarter. FORA Capital LLC bought a new stake in shares of Kenvue in the 1st quarter valued at $981,000. Evergreen Wealth Solutions LLC increased its position in shares of Kenvue by 2.6% in the 1st quarter. Evergreen Wealth Solutions LLC now owns 16,769 shares of the company's stock valued at $402,000 after buying an additional 432 shares in the last quarter. Independent Franchise Partners LLP increased its position in shares of Kenvue by 159.3% in the 1st quarter. Independent Franchise Partners LLP now owns 9,379,037 shares of the company's stock valued at $224,909,000 after buying an additional 5,761,288 shares in the last quarter. Finally, ICONIQ Capital LLC bought a new stake in shares of Kenvue in the 1st quarter valued at $272,000. Institutional investors own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on KVUE. Zacks Research raised shares of Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Royal Bank Of Canada reduced their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating for the company in a research note on Friday, August 8th. Canaccord Genuity Group reduced their target price on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Bank of America reduced their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Finally, Barclays reduced their price objective on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research note on Tuesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $24.38.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.18 on Friday, hitting $20.72. The company had a trading volume of 10,307,391 shares, compared to its average volume of 17,296,208. The stock has a market cap of $39.76 billion, a price-to-earnings ratio of 27.99, a P/E/G ratio of 2.97 and a beta of 0.83. The stock has a 50 day moving average price of $21.46 and a 200 day moving average price of $22.44. Kenvue Inc. has a 1-year low of $19.75 and a 1-year high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. Kenvue's quarterly revenue was down 4.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, August 13th. This is a boost from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.0%. Kenvue's dividend payout ratio (DPR) is presently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.